Cancer radio-immunotherapy, integrating external/internal radiation therapy with immuno-
oncology treatments, emerges in the current management of cancer. A growing number of …

Supramolecular peptide assemblies with specific motifs have the advantages of high
immunogenicity, regulated immune response, and increased multiple functions in improving …

Upregulation of programmed death ligand 1 (PD-L1) allows cancer cells to evade antitumor
immunity. Despite tremendous efforts in developing PD-1/PD-L1 immune checkpoint …

Nanoscale drug delivery systems for cancer treatment have demonstrated promising results
in enhancing the selectivity of therapeutic agents while reducing their toxic side effects …

Cancer immunotherapy (CI) represented by immune checkpoint inhibitors (ICIs) presents a
new paradigm for cancer treatment. However, the types of cancer that attain a therapeutic …

Despite its high potential, PD-L1 expressed by tumors has not been successfully utilized as
a biomarker for estimating treatment responses to immunotherapy. Circulating tumor cells …

This study presents the development of a β-hairpin (tryptophan zipper, Trpzip)-based
molecular tweezer (MT) that can control the folding and binding of α-helical peptides. When …

Blocking the PD-1/PD-L1 immune checkpoint has emerged as a promising strategy in
cancer immunotherapy, in which monoclonal antibodies are predominately used as …

Idiopathic Pulmonary Fibrosis (IPF) is a chronically progressive interstitial lung that affects
over 3 M people worldwide and rising in incidence. With a median survival of 2–3 years, IPF …

Over the past few years, many molecules such as monoclonal antibodies, affibodies,
nanobodies, and small compounds have been designed and tested as inhibitors of PD-1/PD …